eISSN 2508-3589
pISSN 2508-1926

Fig. 2.

Download original image
Fig. 2. Optical coherence tomography images showing clinical course of a patient diagnosed with neovascular age-related macular degeneration. Three months after the third aflibercept injection (A), recurrence was noted with development of intraretinal fluid, subretinal fluid, and subretinal hyperreflective material (SHRM). The intraretinal fluid was not resolved after continuous injections of aflibercept or bevacizumab (B). The treatment method was switched to alternative injection of aflibercept and bevacizumab at 1-month intervals. However, the intraretinal fluid remained (C). The agent was switched to brolucizumab. Two weeks after brolucizumab injection (D), intraretinal fluid was reduced markedly. The fluid did not increase up to the 4-week follow-up (E).
J Retin 2021;6:145-9 https://doi.org/10.21561/jor.2021.6.2.145
© 2021 J Retin